Curigliano, G., O'Shaughnessy, J., Bidard, F. C., Kim, S., Tokunaga, E., Aftimos, P. G., Manich, C. S., Carey, L. A., Okera, M., Melo, Ã., Zagouri, F., Magallanes, M., Karadurmus, N., Bahadur, S. W., Speck, R. M., Wang, X. A., Young, S. R., Jhaveri, K. L., Harbeck, N. (2025). Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1001